{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T16:50:21Z","timestamp":1789145421125,"version":"build-2803163510"},"reference-count":146,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:00:00Z","timestamp":1770854400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:00:00Z","timestamp":1770854400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s40265-025-02280-z","type":"journal-article","created":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T08:00:27Z","timestamp":1770883227000},"page":"411-427","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Current and Future Pharmacological Interventions for Acquired Hypothalamic Obesity"],"prefix":"10.1007","volume":"86","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3037-4057","authenticated-orcid":false,"given":"Christian L.","family":"Roth","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-7267-2090","authenticated-orcid":false,"given":"Nathalie J.","family":"Doelman-Oldenburger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6773-6931","authenticated-orcid":false,"given":"Hanneke M.","family":"van Santen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,12]]},"reference":[{"key":"2280_CR1","doi-asserted-by":"publisher","DOI":"10.1530\/ec-23-0147","author":"I van Roessel","year":"2023","unstructured":"van Roessel I, de Graaf JP, Biermasz NR, Charmandari E, van Santen HM. Acquired hypothalamic dysfunction in childhood: \u201cwhat do patients need?\u201d - an Endo-ERN survey. Endocr Connect. 2023. https:\/\/doi.org\/10.1530\/ec-23-0147.","journal-title":"Endocr Connect"},{"issue":"12","key":"2280_CR2","doi-asserted-by":"publisher","first-page":"5395","DOI":"10.1210\/jc.2010-0993","volume":"95","author":"H Holmer","year":"2010","unstructured":"Holmer H, Pozarek G, Wirf\u00e4lt E, Popovic V, Ekman B, Bj\u00f6rk J, et al. Reduced energy expenditure and impaired feeding-related signals but not high energy intake reinforces hypothalamic obesity in adults with childhood onset craniopharyngioma. J Clin Endocrinol Metab. 2010;95(12):5395\u2013402. https:\/\/doi.org\/10.1210\/jc.2010-0993.","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2280_CR3","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1210\/clinem\/dgac678","volume":"108","author":"AH Shoemaker","year":"2023","unstructured":"Shoemaker AH, Tamaroff J. Approach to the patient with hypothalamic obesity. J Clin Endocrinol Metab. 2023;108(5):1236\u201342. https:\/\/doi.org\/10.1210\/clinem\/dgac678.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2280_CR4","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/s2213-8587(24)00283-3","volume":"13","author":"J Argente","year":"2025","unstructured":"Argente J, Farooqi IS, Chowen JA, K\u00fchnen P, L\u00f3pez M, Morselli E, et al. Hypothalamic obesity: from basic mechanisms to clinical perspectives. Lancet Diabetes Endocrinol. 2025;13(1):57\u201368. https:\/\/doi.org\/10.1016\/s2213-8587(24)00283-3.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2280_CR5","doi-asserted-by":"publisher","DOI":"10.1093\/ejendo\/lvad009","author":"HM van Santen","year":"2023","unstructured":"van Santen HM, van Schaik J, van Roessel I, Beckhaus J, Boekhoff S, M\u00fcller HL. Diagnostic criteria for the hypothalamic syndrome in childhood. Eur J Endocrinol. 2023. https:\/\/doi.org\/10.1093\/ejendo\/lvad009.","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2280_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-022-00351-z","volume":"8","author":"HL M\u00fcller","year":"2022","unstructured":"M\u00fcller HL, Tauber M, Lawson EA, \u00d6zyurt J, Bison B, Martinez-Barbera JP, et al. Hypothalamic syndrome. Nat Rev Dis Primers. 2022;8(1):24. https:\/\/doi.org\/10.1038\/s41572-022-00351-z.","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"2280_CR7","doi-asserted-by":"publisher","first-page":"e76","DOI":"10.1210\/clinem\/dgad488","volume":"109","author":"N Kayadjanian","year":"2023","unstructured":"Kayadjanian N, Hsu EA, Wood AM, Carson DS. Caregiver burden and its relationship to health-related quality of life in craniopharyngioma survivors. J Clin Endocrinol Metab. 2023;109(1):e76\u201387. https:\/\/doi.org\/10.1210\/clinem\/dgad488.","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2280_CR8","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1111\/ijpo.12076","volume":"11","author":"B Haliloglu","year":"2016","unstructured":"Haliloglu B, Atay Z, Guran T, Abal\u0131 S, Bas S, Turan S, et al. Risk factors for mortality caused by hypothalamic obesity in children with hypothalamic tumours. Pediatr Obes. 2016;11(5):383\u20138. https:\/\/doi.org\/10.1111\/ijpo.12076.","journal-title":"Pediatr Obes"},{"issue":"1","key":"2280_CR9","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1007\/s11102-012-0428-2","volume":"16","author":"EM Erfurth","year":"2013","unstructured":"Erfurth EM, Holmer H, Fjalldal SB. Mortality and morbidity in adult craniopharyngioma. Pituitary. 2013;16(1):46\u201355. https:\/\/doi.org\/10.1007\/s11102-012-0428-2.","journal-title":"Pituitary"},{"issue":"2","key":"2280_CR10","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s11060-025-04987-1","volume":"173","author":"HL Muller","year":"2025","unstructured":"Muller HL. Long-term quality of life and hypothalamic dysfunction after craniopharyngioma. J Neurooncol. 2025;173(2):233\u201344. https:\/\/doi.org\/10.1007\/s11060-025-04987-1.","journal-title":"J Neurooncol"},{"key":"2280_CR11","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.ejca.2018.09.016","volume":"104","author":"N Tshuma","year":"2018","unstructured":"Tshuma N, Glynn N, Evanson J, Powles T, Drake WM. Hypothalamitis and severe hypothalamic dysfunction associated with anti-programmed cell death ligand 1 antibody treatment. Eur J Cancer. 2018;104:247\u20139. https:\/\/doi.org\/10.1016\/j.ejca.2018.09.016.","journal-title":"Eur J Cancer"},{"key":"2280_CR12","doi-asserted-by":"publisher","first-page":"1036.e5","DOI":"10.1016\/j.wneu.2017.06.055","volume":"105","author":"L Bertulli","year":"2017","unstructured":"Bertulli L, Bertani GA, Gianelli U, Mantovani G, Rampini PM, Locatelli M. Long-standing isolated autoimmune hypothalamitis diagnosed with endoscopic transventricular biopsy. World Neurosurg. 2017;105:1036.e5-.e9. https:\/\/doi.org\/10.1016\/j.wneu.2017.06.055.","journal-title":"World Neurosurg"},{"key":"2280_CR13","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa247","author":"J Harvengt","year":"2020","unstructured":"Harvengt J, Gernay C, Mastouri M, Farhat N, Lebrethon MC, Seghaye MC, et al. ROHHAD(NET) syndrome: systematic review of the clinical timeline and recommendations for diagnosis and prognosis. J Clin Endocrinol Metab. 2020. https:\/\/doi.org\/10.1210\/clinem\/dgaa247.","journal-title":"J Clin Endocrinol Metab"},{"key":"2280_CR14","doi-asserted-by":"publisher","DOI":"10.1159\/000543544","author":"HM van Santen","year":"2025","unstructured":"van Santen HM. The central control of energy metabolism: hypothalamic obesity is not one disease. Horm Res Paediatr. 2025. https:\/\/doi.org\/10.1159\/000543544.","journal-title":"Horm Res Paediatr"},{"key":"2280_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2025.103313","author":"IMAA van Roessel","year":"2025","unstructured":"van Roessel IMAA, Hulsmann SC, van Schouten- Meeteren AYN, Hoving EW, Janssens GO, Raphael MF, et al. The many different clinical faces of acquired hypothalamic dysfunction: a retrospective cohort study in the Netherlands. eClinicalMedicine. 2025. https:\/\/doi.org\/10.1016\/j.eclinm.2025.103313.","journal-title":"eClinicalMedicine"},{"issue":"6","key":"2280_CR16","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1007\/s11102-020-01065-9","volume":"23","author":"J van Schaik","year":"2020","unstructured":"van Schaik J, Pillen S, van Litsenburg RRL, Vandenbussche NLE, de Bont JM, van Schouten- Meeteren AYN, et al. The importance of specialized sleep investigations in children with a suprasellar tumor. Pituitary. 2020;23(6):613\u201321. https:\/\/doi.org\/10.1007\/s11102-020-01065-9.","journal-title":"Pituitary"},{"issue":"8","key":"2280_CR17","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1016\/j.clnu.2024.05.028","volume":"43","author":"I Van Roessel","year":"2024","unstructured":"Van Roessel I, Van Den Brink M, Dekker J, van Ruitenburg- Essen BG, Tissing WJE, van Santen HM. Feasibility, safety, and efficacy of dietary or lifestyle interventions for hypothalamic obesity: a systematic review. Clin Nutr. 2024;43(8):1798\u2013811. https:\/\/doi.org\/10.1016\/j.clnu.2024.05.028.","journal-title":"Clin Nutr"},{"key":"2280_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1307889","volume":"14","author":"HM van Santen","year":"2023","unstructured":"van Santen HM, Denzer C, M\u00fcller HL. Could setmelanotide be the game-changer for acquired hypothalamic obesity? Front Endocrinol (Lausanne). 2023;14:1307889. https:\/\/doi.org\/10.3389\/fendo.2023.1307889.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"3","key":"2280_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e14411","volume":"9","author":"AR Dassen","year":"2023","unstructured":"Dassen AR, van Schaik J, van den Munckhof P, Schuurman PR, Hoving EW, van Santen HM. Could deep brain stimulation be a possible solution for acquired hypothalamic obesity? Heliyon. 2023;9(3):e14411. https:\/\/doi.org\/10.1016\/j.heliyon.2023.e14411.","journal-title":"Heliyon"},{"key":"2280_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1256514","volume":"14","author":"CL Roth","year":"2023","unstructured":"Roth CL, Zenno A. Treatment of hypothalamic obesity in people with hypothalamic injury: new drugs are on the horizon. Front Endocrinol (Lausanne). 2023;14:1256514. https:\/\/doi.org\/10.3389\/fendo.2023.1256514.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"Suppl 2","key":"2280_CR21","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1111\/dom.15530","volume":"26","author":"CL Roth","year":"2024","unstructured":"Roth CL, McCormack SE. Acquired hypothalamic obesity: a clinical overview and update. Diabetes Obes Metab. 2024;26(Suppl 2):34\u201345. https:\/\/doi.org\/10.1111\/dom.15530.","journal-title":"Diabetes Obes Metab"},{"issue":"5487","key":"2280_CR22","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1126\/science.289.5487.2122","volume":"289","author":"JC Bruning","year":"2000","unstructured":"Bruning JC, Gautam D, Burks DJ, Gillette J, Schubert M, Orban PC, et al. Role of brain insulin receptor in control of body weight and reproduction. Science. 2000;289(5487):2122\u20135. https:\/\/doi.org\/10.1126\/science.289.5487.2122.","journal-title":"Science"},{"issue":"4","key":"2280_CR23","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1053\/beem.2002.0230","volume":"16","author":"A Sainsbury","year":"2002","unstructured":"Sainsbury A, Cooney GJ, Herzog H. Hypothalamic regulation of energy homeostasis. Best Pract Res Clin Endocrinol Metab. 2002;16(4):623\u201337. https:\/\/doi.org\/10.1053\/beem.2002.0230.","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"10","key":"2280_CR24","doi-asserted-by":"publisher","first-page":"4502","DOI":"10.1210\/en.2009-0445","volume":"150","author":"J German","year":"2009","unstructured":"German J, Kim F, Schwartz GJ, Havel PJ, Rhodes CJ, Schwartz MW, et al. Hypothalamic leptin signaling regulates hepatic insulin sensitivity via a neurocircuit involving the vagus nerve. Endocrinology. 2009;150(10):4502\u201311. https:\/\/doi.org\/10.1210\/en.2009-0445.","journal-title":"Endocrinology"},{"issue":"4","key":"2280_CR25","doi-asserted-by":"publisher","first-page":"823","DOI":"10.2337\/db16-1351","volume":"66","author":"GJ Morton","year":"2017","unstructured":"Morton GJ, Muta K, Kaiyala KJ, Rojas JM, Scarlett JM, Matsen ME, et al. Evidence that the sympathetic nervous system elicits rapid, coordinated, and reciprocal adjustments of insulin secretion and insulin sensitivity during cold exposure. Diabetes. 2017;66(4):823\u201334. https:\/\/doi.org\/10.2337\/db16-1351.","journal-title":"Diabetes"},{"issue":"1","key":"2280_CR26","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.molmet.2013.01.002","volume":"2","author":"J Kwon Jeong","year":"2013","unstructured":"Kwon Jeong J, Dae Kim J, Diano S. Ghrelin regulates hypothalamic prolyl carboxypeptidase expression in mice. Mol Metab. 2013;2(1):23\u201330. https:\/\/doi.org\/10.1016\/j.molmet.2013.01.002.","journal-title":"Mol Metab"},{"key":"2280_CR27","doi-asserted-by":"publisher","first-page":"862817","DOI":"10.3389\/fendo.2022.862817","volume":"13","author":"O Abawi","year":"2022","unstructured":"Abawi O, Koster EC, Welling MS, Boeters SCM, van Rossum EFC, van Haelst MM, et al. Resting energy expenditure and body composition in children and adolescents with genetic, hypothalamic, medication-induced or multifactorial severe obesity. Front Endocrinol (Lausanne). 2022;13:862817. https:\/\/doi.org\/10.3389\/fendo.2022.862817.","journal-title":"Front Endocrinol (Lausanne)."},{"issue":"8","key":"2280_CR28","doi-asserted-by":"publisher","first-page":"3993","DOI":"10.1210\/jcem.87.8.8751","volume":"87","author":"HL M\u00fcller","year":"2002","unstructured":"M\u00fcller HL, Handwerker G, Wollny B, Faldum A, S\u00f6rensen N. Melatonin secretion and increased daytime sleepiness in childhood craniopharyngioma patients. J Clin Endocrinol Metab. 2002;87(8):3993\u20136. https:\/\/doi.org\/10.1210\/jcem.87.8.8751.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2280_CR29","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1159\/000530863","volume":"97","author":"EC Hinton","year":"2024","unstructured":"Hinton EC, Lithander FE, Elsworth RL, Hawton K, Narayan K, Szymkowiak S, et al. Evaluating eating behaviour, energy homeostasis, and obesity in childhood-onset craniopharyngioma: a feasibility study. Horm Res Paediatr. 2024;97(1):80\u201393. https:\/\/doi.org\/10.1159\/000530863.","journal-title":"Horm Res Paediatr"},{"issue":"7","key":"2280_CR30","doi-asserted-by":"publisher","first-page":"2601","DOI":"10.1210\/jc.2018-00258","volume":"103","author":"KL Ayers","year":"2018","unstructured":"Ayers KL, Glicksberg BS, Garfield AS, Longerich S, White JA, Yang P, et al. Melanocortin 4 receptor pathway dysfunction in obesity: patient stratification aimed at MC4R agonist treatment. J Clin Endocrinol Metab. 2018;103(7):2601\u201312. https:\/\/doi.org\/10.1210\/jc.2018-00258.","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"2280_CR31","doi-asserted-by":"publisher","first-page":"4732","DOI":"10.1172\/JCI62696","volume":"122","author":"ME Doche","year":"2012","unstructured":"Doche ME, Bochukova EG, Su HW, Pearce LR, Keogh JM, Henning E, et al. Human SH2B1 mutations are associated with maladaptive behaviors and obesity. J Clin Invest. 2012;122(12):4732\u20136. https:\/\/doi.org\/10.1172\/JCI62696.","journal-title":"J Clin Invest"},{"issue":"2","key":"2280_CR32","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1111\/dom.15480","volume":"26","author":"JW Tomlinson","year":"2024","unstructured":"Tomlinson JW. Bardet-biedl syndrome: a focus on genetics, mechanisms and metabolic dysfunction. Diabetes Obes Metab. 2024;26(2):13\u201324. https:\/\/doi.org\/10.1111\/dom.15480.","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"2280_CR33","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.gtc.2023.08.005","volume":"52","author":"JC Han","year":"2023","unstructured":"Han JC, Rasmussen MC, Forte AR, Schrage SB, Zafar SK, Haqq AM. Management of monogenic and syndromic obesity. Gastroenterol Clin North Am. 2023;52(4):733\u201350. https:\/\/doi.org\/10.1016\/j.gtc.2023.08.005.","journal-title":"Gastroenterol Clin North Am"},{"key":"2280_CR34","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.00081","volume":"11","author":"P Loid","year":"2020","unstructured":"Loid P, Mustila T, Makitie RE, Viljakainen H, Kampe A, Tossavainen P, et al. Rare variants in genes linked to appetite control and hypothalamic development in early-onset severe obesity. Front Endocrinol (Lausanne). 2020;11:81. https:\/\/doi.org\/10.3389\/fendo.2020.00081.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2280_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2019.11.017","volume":"19","author":"M Cerbone","year":"2020","unstructured":"Cerbone M, Guemes M, Wade A, Improda N, Dattani M. Endocrine morbidity in midline brain defects: differences between septo-optic dysplasia and related disorders. EClinicalMedicine. 2020;19:100224. https:\/\/doi.org\/10.1016\/j.eclinm.2019.11.017.","journal-title":"EClinicalMedicine"},{"issue":"2","key":"2280_CR36","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1210\/clinem\/dgac583","volume":"108","author":"G Nannette","year":"2023","unstructured":"Nannette G, Bar C, Diene G, Pienkowski C, Oliver-Petit I, Jouret B, et al. Obesity, overweight, and pituitary stalk interruption syndrome in children and young adults. J Clin Endocrinol Metab. 2023;108(2):323\u201330. https:\/\/doi.org\/10.1210\/clinem\/dgac583.","journal-title":"J Clin Endocrinol Metab"},{"key":"2280_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2022.101556","volume":"51","author":"J Hietamaki","year":"2022","unstructured":"Hietamaki J, Karkinen J, Iivonen AP, Vaaralahti K, Tarkkanen A, Almusa H, et al. Presentation and diagnosis of childhood-onset combined pituitary hormone deficiency: a single center experience from over 30 years. EClinicalMedicine. 2022;51:101556. https:\/\/doi.org\/10.1016\/j.eclinm.2022.101556.","journal-title":"EClinicalMedicine"},{"issue":"2","key":"2280_CR38","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1210\/jcem.80.2.7852523","volume":"80","author":"DF Swaab","year":"1995","unstructured":"Swaab DF, Purba JS, Hofman MA. Alterations in the hypothalamic paraventricular nucleus and its oxytocin neurons (putative satiety cells) in Prader-Willi syndrome: a study of five cases. J Clin Endocrinol Metab. 1995;80(2):573\u20139. https:\/\/doi.org\/10.1210\/jcem.80.2.7852523.","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"2280_CR39","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1002\/oby.22315","volume":"26","author":"SR Rose","year":"2018","unstructured":"Rose SR, Horne VE, Bingham N, Jenkins T, Black J, Inge T. Hypothalamic obesity: 4 years of the International Registry of Hypothalamic Obesity Disorders. Obesity. 2018;26(11):1727\u201332. https:\/\/doi.org\/10.1002\/oby.22315.","journal-title":"Obesity"},{"issue":"7","key":"2280_CR40","doi-asserted-by":"publisher","first-page":"3298","DOI":"10.1210\/jc.2003-031751","volume":"89","author":"HL Muller","year":"2004","unstructured":"Muller HL, Emser A, Faldum A, Bruhnken G, Etavard-Gorris N, Gebhardt U, et al. Longitudinal study on growth and body mass index before and after diagnosis of childhood craniopharyngioma. J Clin Endocrinol Metab. 2004;89(7):3298\u2013305. https:\/\/doi.org\/10.1210\/jc.2003-031751.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2280_CR41","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1210\/er.2018-00017","volume":"40","author":"L van Iersel","year":"2019","unstructured":"van Iersel L, Brokke KE, Adan RAH, Bulthuis LCM, van den Akker ELT, van Santen HM. Pathophysiology and individualized treatment of hypothalamic obesity following craniopharyngioma and other suprasellar tumors: a systematic review. Endocr Rev. 2019;40(1):193\u2013235. https:\/\/doi.org\/10.1210\/er.2018-00017.","journal-title":"Endocr Rev"},{"issue":"9","key":"2280_CR42","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.3390\/jcm4091774","volume":"4","author":"CL Roth","year":"2015","unstructured":"Roth CL. Hypothalamic obesity in craniopharyngioma patients: disturbed energy homeostasis related to extent of hypothalamic damage and its implication for obesity intervention. J Clin Med. 2015;4(9):1774\u201397. https:\/\/doi.org\/10.3390\/jcm4091774.","journal-title":"J Clin Med"},{"key":"2280_CR43","doi-asserted-by":"publisher","DOI":"10.1210\/endrev\/bnaf025","author":"HM van Santen","year":"2025","unstructured":"van Santen HM, Muller HL. Management of acquired hypothalamic dysfunction and the hypothalamic syndrome; it is more than obesity. Endocr Rev. 2025. https:\/\/doi.org\/10.1210\/endrev\/bnaf025.","journal-title":"Endocr Rev"},{"issue":"2","key":"2280_CR44","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1159\/000496564","volume":"91","author":"MJ Abuzzahab","year":"2019","unstructured":"Abuzzahab MJ, Roth CL, Shoemaker AH. Hypothalamic obesity: prologue and promise. Horm Res Paediatr. 2019;91(2):128\u201336. https:\/\/doi.org\/10.1159\/000496564.","journal-title":"Horm Res Paediatr"},{"issue":"6","key":"2280_CR45","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/S2213-8587(24)00087-1","volume":"12","author":"CL Roth","year":"2024","unstructured":"Roth CL, Scimia C, Shoemaker AH, Gottschalk M, Miller J, Yuan G, et al. Setmelanotide for the treatment of acquired hypothalamic obesity: a phase 2, open-label, multicentre trial. Lancet Diabetes Endocrinol. 2024;12(6):380\u20139. https:\/\/doi.org\/10.1016\/S2213-8587(24)00087-1.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2280_CR46","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.846880","volume":"13","author":"P Dimitri","year":"2022","unstructured":"Dimitri P. Treatment of acquired hypothalamic obesity: now and the future. Front Endocrinol (Lausanne). 2022;13:846880. https:\/\/doi.org\/10.3389\/fendo.2022.846880.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"5","key":"2280_CR47","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.26911","volume":"65","author":"L van Iersel","year":"2018","unstructured":"van Iersel L, Meijneke RWH, Schouten-van Meeteren AYN, Reneman L, de Win MM, van Trotsenburg ASP, et al. The development of hypothalamic obesity in craniopharyngioma patients: a risk factor analysis in a well-defined cohort. Pediatr Blood Cancer. 2018;65(5):e26911. https:\/\/doi.org\/10.1002\/pbc.26911.","journal-title":"Pediatr Blood Cancer"},{"issue":"1","key":"2280_CR48","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/417949","volume":"2011","author":"JK Hamilton","year":"2011","unstructured":"Hamilton JK, Conwell LS, Syme C, Ahmet A, Jeffery A, Daneman D. Hypothalamic obesity following craniopharyngioma surgery: results of a pilot trial of combined diazoxide and metformin therapy. Int J Pediatr Endocrinol. 2011;2011(1):417949. https:\/\/doi.org\/10.1155\/2011\/417949.","journal-title":"Int J Pediatr Endocrinol"},{"issue":"1-2","key":"2280_CR49","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1515\/jpem-2014-0425","volume":"28","author":"MA Kalina","year":"2015","unstructured":"Kalina MA, Wilczek M, Kalina-Faska B, Ska\u0142a-Zamorowska E, Mandera M, Ma\u0142ecka Tendera E. Carbohydrate-lipid profile and use of metformin with micronized fenofibrate in reducing metabolic consequences of craniopharyngioma treatment in children: single institution experience. J Pediatr Endocrinol Metab. 2015;28(1\u20132):45\u201351. https:\/\/doi.org\/10.1515\/jpem-2014-0425.","journal-title":"J Pediatr Endocrinol Metab"},{"key":"2280_CR50","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2011.00060","volume":"2","author":"RH Lustig","year":"2011","unstructured":"Lustig RH. Hypothalamic obesity after craniopharyngioma: mechanisms, diagnosis, and treatment. Front Endocrinol (Lausanne). 2011;2:60. https:\/\/doi.org\/10.3389\/fendo.2011.00060.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2280_CR51","doi-asserted-by":"publisher","DOI":"10.1530\/ec-22-0276","author":"J Van Schaik","year":"2022","unstructured":"Van Schaik J, Burghard M, Lequin MH, van Maren EA, van Dijk AM, Takken T, et al. Resting energy expenditure in children at risk of hypothalamic dysfunction. Endocr Connect. 2022. https:\/\/doi.org\/10.1530\/ec-22-0276.","journal-title":"Endocr Connect"},{"issue":"9","key":"2280_CR52","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/S2215-0366(18)30269-4","volume":"5","author":"S Cortese","year":"2018","unstructured":"Cortese S, Adamo N, Del Giovane C, Mohr-Jensen C, Hayes AJ, Carucci S, et al. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry. 2018;5(9):727\u201338. https:\/\/doi.org\/10.1016\/S2215-0366(18)30269-4.","journal-title":"Lancet Psychiatry"},{"issue":"9","key":"2280_CR53","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1001\/archpedi.156.9.887","volume":"156","author":"PW Mason","year":"2002","unstructured":"Mason PW, Krawiecki N, Meacham LR. The use of dextroamphetamine to treat obesity and hyperphagia in children treated for craniopharyngioma. Arch Pediatr Adolesc Med. 2002;156(9):887\u201392. https:\/\/doi.org\/10.1001\/archpedi.156.9.887.","journal-title":"Arch Pediatr Adolesc Med"},{"issue":"2","key":"2280_CR54","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1515\/jpem.2006.19.2.129","volume":"19","author":"D Ismail","year":"2006","unstructured":"Ismail D, O\u2019Connell MA, Zacharin MR. Dexamphetamine use for management of obesity and hypersomnolence following hypothalamic injury. J Pediatr Endocrinol Metab. 2006;19(2):129\u201334. https:\/\/doi.org\/10.1515\/jpem.2006.19.2.129.","journal-title":"J Pediatr Endocrinol Metab"},{"issue":"1","key":"2280_CR55","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1159\/000495851","volume":"12","author":"C Denzer","year":"2019","unstructured":"Denzer C, Denzer F, Lennerz BS, Vollbach H, Lustig RH, Wabitsch M. Treatment of hypothalamic obesity with dextroamphetamine: a case series. Obes Facts. 2019;12(1):91\u2013102. https:\/\/doi.org\/10.1159\/000495851.","journal-title":"Obes Facts"},{"key":"2280_CR56","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.845937","volume":"13","author":"J van Schaik","year":"2022","unstructured":"van Schaik J, Welling MS, de Groot CJ, van Eck JP, Juriaans A, Burghard M, et al. Dextroamphetamine treatment in children with hypothalamic obesity. Front Endocrinol (Lausanne). 2022;13:845937. https:\/\/doi.org\/10.3389\/fendo.2022.845937.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2280_CR57","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2011.00078","author":"CT Elfers","year":"2011","unstructured":"Elfers CT, Roth CL. Effects of methylphenidate on weight gain and food intake in hypothalamic obesity. Front Endocrinol. 2011. https:\/\/doi.org\/10.3389\/fendo.2011.00078.","journal-title":"Front Endocrinol"},{"issue":"7","key":"2280_CR58","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.28379","volume":"67","author":"VE Horne","year":"2020","unstructured":"Horne VE, Bielamowicz K, Nguyen J, Hilsenbeck S, Lindsay H, Sonabend R, et al. Methylphenidate improves weight control in childhood brain tumor survivors with hypothalamic obesity. Pediatr Blood Cancer. 2020;67(7):e28379. https:\/\/doi.org\/10.1002\/pbc.28379.","journal-title":"Pediatr Blood Cancer"},{"issue":"1","key":"2280_CR59","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/ijo.2016.185","volume":"41","author":"JR Ryder","year":"2017","unstructured":"Ryder JR, Kaizer A, Rudser KD, Gross A, Kelly AS, Fox CK. Effect of phentermine on weight reduction in a pediatric weight management clinic. Int J Obes (Lond). 2017;41(1):90\u20133. https:\/\/doi.org\/10.1038\/ijo.2016.185.","journal-title":"Int J Obes (Lond)"},{"issue":"6","key":"2280_CR60","doi-asserted-by":"publisher","first-page":"697","DOI":"10.4158\/ep.14.6.697","volume":"14","author":"FL Greenway","year":"2008","unstructured":"Greenway FL, Bray GA. Treatment of hypothalamic obesity with caffeine and ephedrine. Endocr Pract. 2008;14(6):697\u2013703. https:\/\/doi.org\/10.4158\/ep.14.6.697.","journal-title":"Endocr Pract"},{"issue":"4","key":"2280_CR61","first-page":"269","volume":"16","author":"A Astrup","year":"1992","unstructured":"Astrup A, Breum L, Toubro S, Hein P, Quaade F. The effect and safety of an ephedrine\/caffeine compound compared to ephedrine, caffeine and placebo in obese subjects on an energy restricted diet. A double blind trial. Int J Obes Relat Metab Disord. 1992;16(4):269\u201377.","journal-title":"Int J Obes Relat Metab Disord"},{"issue":"1","key":"2280_CR62","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/j.1552-6356.2004.tb00151.x","volume":"8","author":"CD Cockey","year":"2004","unstructured":"Cockey CD. Ephedra banned: consumers advised to stop using ephedra products immediately. AWHONN Lifelines. 2004;8(1):19\u201321. https:\/\/doi.org\/10.1111\/j.1552-6356.2004.tb00151.x.","journal-title":"AWHONN Lifelines"},{"issue":"11","key":"2280_CR63","doi-asserted-by":"publisher","first-page":"3888","DOI":"10.1210\/jc.2016-2118","volume":"101","author":"M Fleseriu","year":"2016","unstructured":"Fleseriu M, Hashim IA, Karavitaki N, Melmed S, Murad MH, Salvatori R, et al. Hormonal replacement in hypopituitarism in adults: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2016;101(11):3888\u2013921. https:\/\/doi.org\/10.1210\/jc.2016-2118.","journal-title":"J Clin Endocrinol Metab"},{"key":"2280_CR64","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2025.101998","author":"L van Iersel","year":"2025","unstructured":"van Iersel L, van Schaik J, van Santen HM. Growth hormone replacement therapy in childhood-onset craniopharyngioma. Best Pract Res Clin Endocrinol Metab. 2025. https:\/\/doi.org\/10.1016\/j.beem.2025.101998.","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"4","key":"2280_CR65","doi-asserted-by":"publisher","first-page":"S27","DOI":"10.1093\/ejendo\/lvaf046","volume":"192","author":"SR van den Oever","year":"2025","unstructured":"van den Oever SR, Mulder RL, Oeffinger KC, Gietema JA, Skinner R, Constine LS, et al. Metabolic syndrome in childhood, adolescent, and young adult cancer survivors: recommendations for surveillance from the International Late Effects of Childhood Cancer Guideline Harmonization Group. Eur J Endocrinol. 2025;192(4):S27-s40. https:\/\/doi.org\/10.1093\/ejendo\/lvaf046.","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"2280_CR66","doi-asserted-by":"publisher","first-page":"P35","DOI":"10.1530\/eje-21-1186","volume":"186","author":"MCS Boguszewski","year":"2022","unstructured":"Boguszewski MCS, Boguszewski CL, Chemaitilly W, Cohen LE, Gebauer J, Higham C, et al. Safety of growth hormone replacement in survivors of cancer and intracranial and pituitary tumours: a consensus statement. Eur J Endocrinol. 2022;186(6):P35-p52. https:\/\/doi.org\/10.1530\/eje-21-1186.","journal-title":"Eur J Endocrinol"},{"key":"2280_CR67","unstructured":"van Schaik J, Verrico A, M\u00fcller HL, Hoving EW, Janssens G, Schouten-van Meeteren AYN, et al. Craniopharyngioma standard clinical practice document. Brain Tumour Group. SIOP Europe; 2021."},{"issue":"5","key":"2280_CR68","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1007\/s11102-021-01173-0","volume":"24","author":"MCS Boguszewski","year":"2021","unstructured":"Boguszewski MCS, Cardoso-Demartini AA, Boguszewski CL, Chemaitilly W, Higham CE, Johannsson G, et al. Safety of growth hormone (GH) treatment in GH deficient children and adults treated for cancer and non-malignant intracranial tumors-a review of research and clinical practice. Pituitary. 2021;24(5):810\u201327. https:\/\/doi.org\/10.1007\/s11102-021-01173-0.","journal-title":"Pituitary"},{"issue":"11","key":"2280_CR69","doi-asserted-by":"publisher","first-page":"5435","DOI":"10.1210\/jc.2004-0667","volume":"89","author":"M Geffner","year":"2004","unstructured":"Geffner M, Lundberg M, Koltowska-H\u00e4ggstr\u00f6m M, Abs R, Verhelst J, Erfurth EM, et al. Changes in height, weight, and body mass index in children with craniopharyngioma after three years of growth hormone therapy: analysis of KIGS (Pfizer International Growth Database). J Clin Endocrinol Metab. 2004;89(11):5435\u201340. https:\/\/doi.org\/10.1210\/jc.2004-0667.","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2280_CR70","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1530\/eje-18-0505","volume":"179","author":"S Boekhoff","year":"2018","unstructured":"Boekhoff S, Bogusz A, Sterkenburg AS, Eveslage M, M\u00fcller HL. Long-term effects of growth hormone replacement therapy in childhood-onset craniopharyngioma: results of the German Craniopharyngioma Registry (HIT-Endo). Eur J Endocrinol. 2018;179(5):331\u201341. https:\/\/doi.org\/10.1530\/eje-18-0505.","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"2280_CR71","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.bbmt.2016.12.623","volume":"23","author":"DN Friedman","year":"2017","unstructured":"Friedman DN, Hilden P, Moskowitz CS, Suzuki M, Boulad F, Kernan NA, et al. Cardiovascular risk factors in survivors of childhood hematopoietic cell transplantation treated with total body irradiation: a longitudinal analysis. Biol Blood Marrow Transplant. 2017;23(3):475\u201382. https:\/\/doi.org\/10.1016\/j.bbmt.2016.12.623.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"2280_CR72","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/j.eprac.2025.02.005","volume":"31","author":"A Dharia","year":"2025","unstructured":"Dharia A, Desai D, Desai K. Exploring the link between thyroid disorders and obesity: mechanisms, impacts, and clinical implications. Endocr Pract. 2025;31(5):660\u20137. https:\/\/doi.org\/10.1016\/j.eprac.2025.02.005.","journal-title":"Endocr Pract"},{"issue":"11","key":"2280_CR73","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1053\/meta.2002.35591","volume":"51","author":"JK Fernandes","year":"2002","unstructured":"Fernandes JK, Klein MJ, Ater JL, Kuttesch JF, Vassilopoulou-Sellin R. Triiodothyronine supplementation for hypothalamic obesity. Metabolism. 2002;51(11):1381\u20133. https:\/\/doi.org\/10.1053\/meta.2002.35591.","journal-title":"Metabolism"},{"issue":"1\u20132","key":"2280_CR74","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1515\/jpem-2014-0337","volume":"28","author":"HM van Santen","year":"2015","unstructured":"van Santen HM, Schouten-Meeteren AY, Serlie M, Meijneke RW, van Trotsenburg AS, Verberne H, et al. Effects of T3 treatment on brown adipose tissue and energy expenditure in a patient with craniopharyngioma and hypothalamic obesity. J Pediatr Endocrinol Metab. 2015;28(1\u20132):53\u20137. https:\/\/doi.org\/10.1515\/jpem-2014-0337.","journal-title":"J Pediatr Endocrinol Metab"},{"issue":"2","key":"2280_CR75","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1007\/s12020-016-1084-5","volume":"54","author":"AM Daubenb\u00fcchel","year":"2016","unstructured":"Daubenb\u00fcchel AM, Hoffmann A, Eveslage M, \u00d6zyurt J, Lohle K, Reichel J, et al. Oxytocin in\u00a0survivors of childhood-onset craniopharyngioma. Endocrine. 2016;54(2):524\u201331. https:\/\/doi.org\/10.1007\/s12020-016-1084-5.","journal-title":"Endocrine"},{"issue":"4","key":"2280_CR76","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/s11154-013-9260-x","volume":"14","author":"JE Blevins","year":"2013","unstructured":"Blevins JE, Ho JM. Role of oxytocin signaling in the regulation of body weight. Rev Endocr Metab Disord. 2013;14(4):311\u201329. https:\/\/doi.org\/10.1007\/s11154-013-9260-x.","journal-title":"Rev Endocr Metab Disord"},{"issue":"1","key":"2280_CR77","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s12020-017-1257-x","volume":"56","author":"A Hoffmann","year":"2017","unstructured":"Hoffmann A, Lohle K, Reichel J, Thiel CM, M\u00fcller HL. First experiences with neuropsychological effects of oxytocin administration in childhood-onset craniopharyngioma. Endocrine. 2017;56(1):175\u201385. https:\/\/doi.org\/10.1007\/s12020-017-1257-x.","journal-title":"Endocrine"},{"issue":"5","key":"2280_CR78","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvad037","volume":"7","author":"SE McCormack","year":"2023","unstructured":"McCormack SE, Wang Z, Wade KL, Dedio A, Cilenti N, Crowley J, et al. A pilot randomized clinical trial of intranasal oxytocin to promote weight loss in individuals with hypothalamic obesity. J Endocr Soc. 2023;7(5):bvad037. https:\/\/doi.org\/10.1210\/jendso\/bvad037.","journal-title":"J Endocr Soc"},{"issue":"2","key":"2280_CR79","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1210\/jc.2017-02080","volume":"103","author":"EA Hsu","year":"2018","unstructured":"Hsu EA, Miller JL, Perez FA, Roth CL. Oxytocin and naltrexone successfully treat hypothalamic obesity in a boy post-craniopharyngioma resection. J Clin Endocrinol Metab. 2018;103(2):370\u20135. https:\/\/doi.org\/10.1210\/jc.2017-02080.","journal-title":"J Clin Endocrinol Metab"},{"key":"2280_CR80","doi-asserted-by":"publisher","DOI":"10.1002\/ncp.11348","author":"B Dunn","year":"2025","unstructured":"Dunn B, Foxe M, Sprott KH, Hook JE, Jump C. The use of octreotide in pediatric patients: practical applications for gastrointestinal disorders and beyond: a narrative review. Nutr Clin Pract. 2025. https:\/\/doi.org\/10.1002\/ncp.11348.","journal-title":"Nutr Clin Pract"},{"issue":"6","key":"2280_CR81","doi-asserted-by":"publisher","first-page":"2586","DOI":"10.1210\/jc.2002-030003","volume":"88","author":"RH Lustig","year":"2003","unstructured":"Lustig RH, Hinds PS, Ringwald-Smith K, Christensen RK, Kaste SC, Schreiber RE, et al. Octreotide therapy of pediatric hypothalamic obesity: a double-blind, placebo-controlled trial. J Clin Endocrinol Metab. 2003;88(6):2586\u201392. https:\/\/doi.org\/10.1210\/jc.2002-030003.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2280_CR82","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S0022-3476(99)70017-X","volume":"135","author":"RH Lustig","year":"1999","unstructured":"Lustig RH, Rose SR, Burghen GA, Velasquez-Mieyer P, Broome DC, Smith K, et al. Hypothalamic obesity caused by cranial insult in children: altered glucose and insulin dynamics and reversal by a somatostatin agonist. J Pediatr. 1999;135(2):162\u20138. https:\/\/doi.org\/10.1016\/S0022-3476(99)70017-X.","journal-title":"J Pediatr"},{"issue":"2","key":"2280_CR83","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1038\/sj.ijo.0803074","volume":"30","author":"RH Lustig","year":"2006","unstructured":"Lustig RH, Greenway F, Velasquez-Mieyer P, Heimburger D, Schumacher D, Smith D, et al. A multicenter, randomized, double-blind, placebo-controlled, dose-finding trial of a long-acting formulation of octreotide in promoting weight loss in obese adults with insulin hypersecretion. Int J Obes (Lond). 2006;30(2):331\u201341. https:\/\/doi.org\/10.1038\/sj.ijo.0803074.","journal-title":"Int J Obes (Lond)"},{"issue":"2","key":"2280_CR84","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1007\/s13679-019-00335-3","volume":"8","author":"A Yerevanian","year":"2019","unstructured":"Yerevanian A, Soukas AA. Metformin: mechanisms in human obesity and weight loss. Curr Obes Rep. 2019;8(2):156\u201364. https:\/\/doi.org\/10.1007\/s13679-019-00335-3.","journal-title":"Curr Obes Rep"},{"issue":"2","key":"2280_CR85","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1210\/en.2006-1237","volume":"148","author":"C Chau-Van","year":"2007","unstructured":"Chau-Van C, Gamba M, Salvi R, Gaillard RC, Pralong FoP. Metformin inhibits adenosine 5\u2032-monophosphate-activated kinase activation and prevents increases in neuropeptide Y expression in cultured hypothalamic neurons. Endocrinology. 2007;148(2):507\u201311. https:\/\/doi.org\/10.1210\/en.2006-1237.","journal-title":"Endocrinology"},{"issue":"7","key":"2280_CR86","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/nrendo.2016.67","volume":"12","author":"M L\u00f3pez","year":"2016","unstructured":"L\u00f3pez M, Nogueiras R, Tena-Sempere M, Di\u00e9guez C. Hypothalamic AMPK: a canonical regulator of whole-body energy balance. Nat Rev Endocrinol. 2016;12(7):421\u201332. https:\/\/doi.org\/10.1038\/nrendo.2016.67.","journal-title":"Nat Rev Endocrinol"},{"key":"2280_CR87","doi-asserted-by":"publisher","DOI":"10.3390\/children8070531","author":"D Tessaris","year":"2021","unstructured":"Tessaris D, Matarazzo P, Tuli G, Tuscano A, Rabbone I, Spinardi A, et al. Multidisciplinary approach for hypothalamic obesity in children and adolescents: a preliminary study. Children. 2021. https:\/\/doi.org\/10.3390\/children8070531.","journal-title":"Children"},{"issue":"1","key":"2280_CR88","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1210\/js.2017-00300","volume":"2","author":"V Cacciatori","year":"2018","unstructured":"Cacciatori V, Zoppini G, Bellavere F, Rigolon R, Thomaseth K, Pichiri I, et al. Long-acting GLP-1 receptor agonist exenatide influence on the autonomic cardiac sympatho-vagal balance. J Endocr Soc. 2018;2(1):53\u201362. https:\/\/doi.org\/10.1210\/js.2017-00300.","journal-title":"J Endocr Soc."},{"key":"2280_CR89","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.133429","author":"S Gabery","year":"2020","unstructured":"Gabery S, Salinas CG, Paulsen SJ, Ahnfelt-Ronne J, Alanentalo T, Baquero AF, et al. Semaglutide lowers body weight in rodents via distributed neural pathways. JCI Insight. 2020. https:\/\/doi.org\/10.1172\/jci.insight.133429.","journal-title":"JCI Insight."},{"issue":"1","key":"2280_CR90","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1159\/000338464","volume":"78","author":"CT Elfers","year":"2012","unstructured":"Elfers CT, Simmons JH, Roth CL. Glucagon-like peptide-1 agonist exendin-4 leads to reduction of weight and caloric intake in a rat model of hypothalamic obesity. Horm Res Paediatr. 2012;78(1):47\u201353. https:\/\/doi.org\/10.1159\/000338464.","journal-title":"Horm Res Paediatr"},{"issue":"7","key":"2280_CR91","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1056\/NEJMoa1903822","volume":"381","author":"WV Tamborlane","year":"2019","unstructured":"Tamborlane WV, Barrientos-Perez M, Fainberg U, Frimer-Larsen H, Hafez M, Hale PM, et al. Liraglutide in children and adolescents with type 2 diabetes. N Engl J Med. 2019;381(7):637\u201346. https:\/\/doi.org\/10.1056\/NEJMoa1903822.","journal-title":"N Engl J Med"},{"issue":"22","key":"2280_CR92","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1916038","volume":"382","author":"AS Kelly","year":"2020","unstructured":"Kelly AS, Auerbach P, Barrientos-Perez M, Gies I, Hale PM, Marcus C, et al. A randomized, controlled trial of liraglutide for adolescents with obesity. N Engl J Med. 2020;382(22):2117\u201328. https:\/\/doi.org\/10.1056\/NEJMoa1916038.","journal-title":"N Engl J Med"},{"issue":"1","key":"2280_CR93","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1159\/000339469","volume":"78","author":"JH Simmons","year":"2012","unstructured":"Simmons JH, Shoemaker AH, Roth CL. Treatment with glucagon-like peptide-1 agonist exendin-4 in a patient with hypothalamic obesity secondary to intracranial tumor. Horm Res Paediatr. 2012;78(1):54\u20138. https:\/\/doi.org\/10.1159\/000339469.","journal-title":"Horm Res Paediatr"},{"issue":"1","key":"2280_CR94","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvae200","volume":"9","author":"P Dimitri","year":"2024","unstructured":"Dimitri P, Roth CL. Treatment of hypothalamic obesity with GLP-1 analogs. J Endocr Soc. 2024;9(1):bvae200. https:\/\/doi.org\/10.1210\/jendso\/bvae200.","journal-title":"J Endocr Soc"},{"issue":"4","key":"2280_CR95","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1093\/ejendo\/lvae024","volume":"190","author":"B Gatta-Cherifi","year":"2024","unstructured":"Gatta-Cherifi B, Mohammedi K, Cariou T, Poitou C, Touraine P, Raverot G, et al. Impact of exenatide on weight loss and eating behavior in adults with craniopharyngioma-related obesity: the CRANIOEXE randomized placebo-controlled trial. Eur J Endocrinol. 2024;190(4):257\u201365. https:\/\/doi.org\/10.1093\/ejendo\/lvae024.","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"2280_CR96","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1111\/dom.14224","volume":"23","author":"CL Roth","year":"2021","unstructured":"Roth CL, Perez FA, Whitlock KB, Elfers C, Yanovski JA, Shoemaker AH, et al. A phase 3 randomized clinical trial using a once-weekly glucagon-like peptide-1 receptor agonist in adolescents and young adults with hypothalamic obesity. Diabetes Obes Metab. 2021;23(2):363\u201373. https:\/\/doi.org\/10.1111\/dom.14224.","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"2280_CR97","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1038\/s41366-021-01043-6","volume":"46","author":"AH Shoemaker","year":"2022","unstructured":"Shoemaker AH, Silver HJ, Buchowski M, Slaughter JC, Yanovski JA, Elfers C, et al. Energy balance in hypothalamic obesity in response to treatment with a once-weekly GLP-1 receptor agonist. Int J Obes (Lond). 2022;46(3):623\u20139. https:\/\/doi.org\/10.1038\/s41366-021-01043-6.","journal-title":"Int J Obes (Lond)"},{"issue":"5","key":"2280_CR98","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-025-01564-7","volume":"28","author":"E Gjersdal","year":"2025","unstructured":"Gjersdal E, Klit F\u00d8, Schmidt Ettrup K, Vestergaard P, Nielsen EH, Vistisen KN, et al. Semaglutide treatment in hypothalamic obesity: two-year outcomes on body composition, appetite, and quality of life. Pituitary. 2025;28(5):93. https:\/\/doi.org\/10.1007\/s11102-025-01564-7.","journal-title":"Pituitary"},{"issue":"3","key":"2280_CR99","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1111\/cen.15262","volume":"103","author":"X Wang","year":"2025","unstructured":"Wang X, Ma H, Wang F, Long H, Li C, Nie M, et al. The efficacy of semaglutide on hypothalamic obesity caused by craniopharyngioma surgery. Clin Endocrinol. 2025;103(3):359\u201365. https:\/\/doi.org\/10.1111\/cen.15262.","journal-title":"Clin Endocrinol"},{"issue":"1","key":"2280_CR100","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.aed.2025.03.004","volume":"12","author":"S Brijmohan","year":"2025","unstructured":"Brijmohan S, Mullally JA. Successful treatment of hypothalamic obesity with tirzepatide. AACE Endocrinol Diabetes. 2025;12(1):30\u20133. https:\/\/doi.org\/10.1016\/j.aed.2025.03.004.","journal-title":"AACE Endocrinol Diabetes"},{"issue":"1","key":"2280_CR101","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-01931-z","volume":"9","author":"Z Zheng","year":"2024","unstructured":"Zheng Z, Zong Y, Ma Y, Tian Y, Pang Y, Zhang C, et al. Glucagon-like peptide-1 receptor: mechanisms and advances in therapy. Signal Transduct Target Ther. 2024;9(1):234. https:\/\/doi.org\/10.1038\/s41392-024-01931-z.","journal-title":"Signal Transduct Target Ther"},{"issue":"11","key":"2280_CR102","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","volume":"384","author":"JPH Wilding","year":"2021","unstructured":"Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989\u20131002. https:\/\/doi.org\/10.1056\/NEJMoa2032183.","journal-title":"N Engl J Med"},{"issue":"3","key":"2280_CR103","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/NEJMoa2206038","volume":"387","author":"AM Jastreboff","year":"2022","unstructured":"Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205\u201316. https:\/\/doi.org\/10.1056\/NEJMoa2206038.","journal-title":"N Engl J Med"},{"key":"2280_CR104","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2301972","author":"AM Jastreboff","year":"2023","unstructured":"Jastreboff AM, Kaplan LM, Frias JP, Wu Q, Du Y, Gurbuz S, et al. Triple-hormone-receptor agonist retatrutide for obesity - a phase 2 trial. N Engl J Med. 2023. https:\/\/doi.org\/10.1056\/NEJMoa2301972.","journal-title":"N Engl J Med"},{"issue":"3","key":"2280_CR105","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1111\/dom.12824","volume":"19","author":"K Bettge","year":"2017","unstructured":"Bettge K, Kahle M, Abd El Aziz MS, Meier JJ, Nauck MA. Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: a systematic analysis of published clinical trials. Diabetes Obes Metab. 2017;19(3):336\u201347. https:\/\/doi.org\/10.1111\/dom.12824.","journal-title":"Diabetes Obes Metab"},{"key":"2280_CR106","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.2147\/PPA.S277676","volume":"14","author":"T Weiss","year":"2020","unstructured":"Weiss T, Carr RD, Pal S, Yang L, Sawhney B, Boggs R, et al. Real-world adherence and discontinuation of glucagon-like peptide-1 receptor agonists therapy in type 2 diabetes mellitus patients in the United States. Patient Prefer Adherence. 2020;14:2337\u201345. https:\/\/doi.org\/10.2147\/PPA.S277676.","journal-title":"Patient Prefer Adherence"},{"issue":"2","key":"2280_CR107","doi-asserted-by":"publisher","first-page":"384","DOI":"10.2337\/dc22-1148","volume":"46","author":"J Bezin","year":"2023","unstructured":"Bezin J, Gouverneur A, Penichon M, Mathieu C, Garrel R, Hillaire-Buys D, et al. GLP-1 receptor agonists and the risk of thyroid cancer. Diabetes Care. 2023;46(2):384\u201390. https:\/\/doi.org\/10.2337\/dc22-1148.","journal-title":"Diabetes Care"},{"issue":"24","key":"2280_CR108","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1056\/NEJMoa2208601","volume":"387","author":"D Weghuber","year":"2022","unstructured":"Weghuber D, Barrett T, Barrientos-Perez M, Gies I, Hesse D, Jeppesen OK, et al. Once-weekly semaglutide in adolescents with obesity. N Engl J Med. 2022;387(24):2245\u201357. https:\/\/doi.org\/10.1056\/NEJMoa2208601.","journal-title":"N Engl J Med"},{"issue":"8","key":"2280_CR109","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1111\/dom.14725","volume":"24","author":"JPH Wilding","year":"2022","unstructured":"Wilding JPH, Batterham RL, Davies M, Van Gaal LF, Kandler K, Konakli K, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553\u201364. https:\/\/doi.org\/10.1111\/dom.14725.","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"2280_CR110","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1097\/crd.0000000000000513","volume":"32","author":"AM D'Ascanio","year":"2024","unstructured":"D\u2019Ascanio AM, Mullally JA, Frishman WH. Cagrilintide: a long-acting amylin analog for the treatment of obesity. Cardiol Rev. 2024;32(1):83\u201390. https:\/\/doi.org\/10.1097\/crd.0000000000000513.","journal-title":"Cardiol Rev"},{"key":"2280_CR111","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.biochi.2024.10.012","volume":"229","author":"MK Hankir","year":"2025","unstructured":"Hankir MK, Le Foll C. Central nervous system pathways targeted by amylin in the regulation of food intake. Biochimie. 2025;229:95\u2013104. https:\/\/doi.org\/10.1016\/j.biochi.2024.10.012.","journal-title":"Biochimie"},{"issue":"6778","key":"2280_CR112","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1038\/35007534","volume":"404","author":"MW Schwartz","year":"2000","unstructured":"Schwartz MW, Woods SC, Porte D Jr., Seeley RJ, Baskin DG. Central nervous system control of food intake. Nature. 2000;404(6778):661\u201371. https:\/\/doi.org\/10.1038\/35007534.","journal-title":"Nature"},{"issue":"3","key":"2280_CR113","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1038\/s41366-025-01734-4","volume":"49","author":"M Pasarica","year":"2025","unstructured":"Pasarica M, Dhurandhar NV, Stensel DJ. Obesity management with next-generation drugs. Int J Obes (Lond). 2025;49(3):367\u20138. https:\/\/doi.org\/10.1038\/s41366-025-01734-4.","journal-title":"Int J Obes (Lond)"},{"key":"2280_CR114","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.neuropharm.2019.02.020","volume":"149","author":"D Vallof","year":"2019","unstructured":"Vallof D, Vestlund J, Jerlhag E. Glucagon-like peptide-1 receptors within the nucleus of the solitary tract regulate alcohol-mediated behaviors in rodents. Neuropharmacology. 2019;149:124\u201332. https:\/\/doi.org\/10.1016\/j.neuropharm.2019.02.020.","journal-title":"Neuropharmacology"},{"key":"2280_CR115","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.3224","author":"D Rubino","year":"2021","unstructured":"Rubino D, Abrahamsson N, Davies M, Hesse D, Greenway FL, Jensen C, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA. 2021. https:\/\/doi.org\/10.1001\/jama.2021.3224.","journal-title":"JAMA"},{"key":"2280_CR116","doi-asserted-by":"publisher","DOI":"10.1172\/JCI174597","author":"Y Gou","year":"2023","unstructured":"Gou Y, Schwartz MW. How should we think about the unprecedented weight loss efficacy of incretin-mimetic drugs? J Clin Invest. 2023. https:\/\/doi.org\/10.1172\/JCI174597.","journal-title":"J Clin Invest"},{"key":"2280_CR117","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2021.101352","volume":"54","author":"Y Dong","year":"2021","unstructured":"Dong Y, Carty J, Goldstein N, He Z, Hwang E, Chau D, et al. Time and metabolic state-dependent effects of GLP-1R agonists on NPY\/AgRP and POMC neuronal activity in vivo. Mol Metab. 2021;54:101352. https:\/\/doi.org\/10.1016\/j.molmet.2021.101352.","journal-title":"Mol Metab"},{"issue":"12","key":"2280_CR118","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1038\/nn.4392","volume":"19","author":"AS Garfield","year":"2016","unstructured":"Garfield AS, Shah BP, Burgess CR, Li MM, Li C, Steger JS, et al. Dynamic GABAergic afferent modulation of AgRP neurons. Nat Neurosci. 2016;19(12):1628\u201335. https:\/\/doi.org\/10.1038\/nn.4392.","journal-title":"Nat Neurosci"},{"issue":"4","key":"2280_CR119","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1111\/bcp.14210","volume":"86","author":"IJ Onakpoya","year":"2020","unstructured":"Onakpoya IJ, Lee JJ, Mahtani KR, Aronson JK, Heneghan CJ. Naltrexone-bupropion (Mysimba) in management of obesity: a systematic review and meta-analysis of unpublished clinical study reports. Br J Clin Pharmacol. 2020;86(4):646\u201367. https:\/\/doi.org\/10.1111\/bcp.14210.","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"2280_CR120","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1038\/ijo.2013.145","volume":"38","author":"GJ Wang","year":"2014","unstructured":"Wang GJ, Tomasi D, Volkow ND, Wang R, Telang F, Caparelli EC, et al. Effect of combined naltrexone and bupropion therapy on the brain\u2019s reactivity to food cues. Int J Obes. 2014;38(5):682\u20138. https:\/\/doi.org\/10.1038\/ijo.2013.145.","journal-title":"Int J Obes"},{"issue":"3","key":"2280_CR121","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1007\/s40519-020-00910-x","volume":"26","author":"EA Carbone","year":"2021","unstructured":"Carbone EA, Caroleo M, Rania M, Calabr\u00f2 G, Staltari FA, de Filippis R, et al. An open-label trial on the efficacy and tolerability of naltrexone\/bupropion SR for treating altered eating behaviours and weight loss in binge eating disorder. Eat Weight Disord. 2021;26(3):779\u201388. https:\/\/doi.org\/10.1007\/s40519-020-00910-x.","journal-title":"Eat Weight Disord"},{"issue":"1-3","key":"2280_CR122","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.ejphar.2010.03.026","volume":"636","author":"HH Hansen","year":"2010","unstructured":"Hansen HH, Hansen G, Tang-Christensen M, Larsen PJ, Axel AM, Raben A, et al. The novel triple monoamine reuptake inhibitor tesofensine induces sustained weight loss and improves glycemic control in the diet-induced obese rat: comparison to sibutramine and rimonabant. Eur J Pharmacol. 2010;636(1\u20133):88\u201395. https:\/\/doi.org\/10.1016\/j.ejphar.2010.03.026.","journal-title":"Eur J Pharmacol"},{"issue":"6","key":"2280_CR123","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1530\/EJE-21-0972","volume":"186","author":"K Huynh","year":"2022","unstructured":"Huynh K, Klose M, Krogsgaard K, Drejer J, Byberg S, Madsbad S, et al. Randomized controlled trial of Tesomet for weight loss in hypothalamic obesity. Eur J Endocrinol. 2022;186(6):687\u2013700. https:\/\/doi.org\/10.1530\/EJE-21-0972.","journal-title":"Eur J Endocrinol"},{"key":"2280_CR124","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2021.101206","volume":"48","author":"GSH Yeo","year":"2021","unstructured":"Yeo GSH, Chao DHM, Siegert AM, Koerperich ZM, Ericson MD, Simonds SE, et al. The melanocortin pathway and energy homeostasis: from discovery to obesity therapy. Mol Metab. 2021;48:101206. https:\/\/doi.org\/10.1016\/j.molmet.2021.101206.","journal-title":"Mol Metab"},{"issue":"10","key":"2280_CR125","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/j.molmet.2016.07.009","volume":"5","author":"PJ Enriori","year":"2016","unstructured":"Enriori PJ, Chen W, Garcia-Rudaz MC, Grayson BE, Evans AE, Comstock SM, et al. alpha-Melanocyte stimulating hormone promotes muscle glucose uptake via melanocortin 5 receptors. Mol Metab. 2016;5(10):807\u201322. https:\/\/doi.org\/10.1016\/j.molmet.2016.07.009.","journal-title":"Mol Metab."},{"issue":"2","key":"2280_CR126","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.metabol.2009.06.031","volume":"59","author":"CL Roth","year":"2010","unstructured":"Roth CL, Enriori PJ, Gebhardt U, Hinney A, M\u00fcller HL, Hebebrand J, et al. Changes of peripheral alpha-melanocyte-stimulating hormone in childhood obesity. Metabolism. 2010;59(2):186\u201394. https:\/\/doi.org\/10.1016\/j.metabol.2009.06.031.","journal-title":"Metabolism"},{"issue":"1","key":"2280_CR127","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1530\/eje.0.1380089","volume":"138","author":"C Roth","year":"1998","unstructured":"Roth C, Wilken B, Hanefeld F, Schr\u00f6ter W, Leonhardt U. Hyperphagia in children with craniopharyngioma is associated with hyperleptinaemia and a failure in the downregulation of appetite. Eur J Endocrinol. 1998;138(1):89\u201391. https:\/\/doi.org\/10.1530\/eje.0.1380089.","journal-title":"Eur J Endocrinol"},{"issue":"7","key":"2280_CR128","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1515\/jpem.2002.15.7.963","volume":"15","author":"L Patel","year":"2002","unstructured":"Patel L, Cooper CD, Quinton ND, Butler GE, Gill MS, Jefferson IG, et al. Serum leptin and leptin binding activity in children and adolescents with hypothalamic dysfunction. J Pediatr Endocrinol Metab. 2002;15(7):963\u201371. https:\/\/doi.org\/10.1515\/jpem.2002.15.7.963.","journal-title":"J Pediatr Endocrinol Metab"},{"issue":"6","key":"2280_CR129","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1530\/eje-08-0533","volume":"159","author":"MG Shaikh","year":"2008","unstructured":"Shaikh MG, Grundy RG, Kirk JM. Hyperleptinaemia rather than fasting hyperinsulinaemia is associated with obesity following hypothalamic damage in children. Eur J Endocrinol. 2008;159(6):791\u20137. https:\/\/doi.org\/10.1530\/eje-08-0533.","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"2280_CR130","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1056\/NEJMoa1512693","volume":"375","author":"P Kuhnen","year":"2016","unstructured":"Kuhnen P, Clement K, Wiegand S, Blankenstein O, Gottesdiener K, Martini LL, et al. Proopiomelanocortin deficiency treated with a melanocortin-4 receptor agonist. N Engl J Med. 2016;375(3):240\u20136. https:\/\/doi.org\/10.1056\/NEJMoa1512693.","journal-title":"N Engl J Med"},{"issue":"12","key":"2280_CR131","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1016\/S2213-8587(20)30364-8","volume":"8","author":"K Clement","year":"2020","unstructured":"Clement K, van den Akker E, Argente J, Bahm A, Chung WK, Connors H, et al. Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials. Lancet Diabetes Endocrinol. 2020;8(12):960\u201370. https:\/\/doi.org\/10.1016\/S2213-8587(20)30364-8.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"11","key":"2280_CR132","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1111\/dom.14133","volume":"22","author":"R Haws","year":"2020","unstructured":"Haws R, Brady S, Davis E, Fletty K, Yuan G, Gordon G, et al. Effect of setmelanotide, a melanocortin-4 receptor agonist, on obesity in Bardet-Biedl syndrome. Diabetes Obes Metab. 2020;22(11):2133\u201340. https:\/\/doi.org\/10.1111\/dom.14133.","journal-title":"Diabetes Obes Metab"},{"issue":"10","key":"2280_CR133","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1016\/j.molmet.2017.06.015","volume":"6","author":"TH Collet","year":"2017","unstructured":"Collet TH, Dubern B, Mokrosinski J, Connors H, Keogh JM, Mendes de Oliveira E, et al. Evaluation of a melanocortin-4 receptor (MC4R) agonist (Setmelanotide) in MC4R deficiency. Mol Metab. 2017;6(10):1321\u20139. https:\/\/doi.org\/10.1016\/j.molmet.2017.06.015.","journal-title":"Mol Metab."},{"key":"2280_CR134","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvaf149.074","author":"SA Phillips","year":"2025","unstructured":"Phillips SA, van Santen HM, Hamilton JK, Shoemaker AH, McCormack SE, Abuzzahab MJ, et al. OR11-01 efficacy and safety of setmelanotide in acquired hypothalamic obesity: results from a double-blind, multicenter, placebo-controlled, randomized phase 3 trial. J Endocr Soc. 2025. https:\/\/doi.org\/10.1210\/jendso\/bvaf149.074.","journal-title":"J Endocr Soc."},{"key":"2280_CR135","unstructured":"RhythmPharmaceuticals. Rhythm Pharmaceuticals Announces Oral MC4R Agonist Bivamelagon Achieved Statistically Significant, Clinically Meaningful BMI Reductions in Placebo-controlled Phase 2 Trial in Acquired Hypothalamic Obesity. In: News Release Details. Rhythm Pharmaceuticals, Inc. July 9, 2025 [Available from: https:\/\/ir.rhythmtx.com\/news-releases\/news-release-details\/rhythm-pharmaceuticals-announces-oral-mc4r-agonist-bivamelagon\/. Accessed 12 Sep 2025."},{"key":"2280_CR136","doi-asserted-by":"publisher","DOI":"10.1530\/ec-24-0533","author":"SC Hulsmann","year":"2025","unstructured":"Hulsmann SC, Hoving E, Bakker B, Janssens Go, van Schaik J, de Vos-Kerkhof E, et al. BMI trajectories in the first 3 months after childhood craniopharyngioma resection: a plea for early management of BMI changes. Endocr Connect. 2025. https:\/\/doi.org\/10.1530\/ec-24-0533.","journal-title":"Endocr Connect"},{"issue":"3","key":"2280_CR137","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1210\/endrev\/bnad033","volume":"45","author":"H-W Gan","year":"2023","unstructured":"Gan H-W, Cerbone M, Dattani MT. Appetite- and weight-regulating neuroendocrine circuitry in hypothalamic obesity. Endocr Rev. 2023;45(3):309\u201342. https:\/\/doi.org\/10.1210\/endrev\/bnad033.","journal-title":"Endocr Rev"},{"issue":"3","key":"2280_CR138","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1152\/physrev.00031.2017","volume":"98","author":"B Jurek","year":"2018","unstructured":"Jurek B, Neumann ID. The oxytocin receptor: from intracellular signaling to behavior. Physiol Rev. 2018;98(3):1805\u2013908. https:\/\/doi.org\/10.1152\/physrev.00031.2017.","journal-title":"Physiol Rev"},{"issue":"9","key":"2280_CR139","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.2337\/dbi21-0002","volume":"70","author":"RJ Samms","year":"2021","unstructured":"Samms RJ, Sloop KW, Gribble FM, Reimann F, Adriaenssens AE. GIPR function in the central nervous system: implications and novel perspectives for GIP-based therapies in treating metabolic disorders. Diabetes. 2021;70(9):1938\u201344. https:\/\/doi.org\/10.2337\/dbi21-0002.","journal-title":"Diabetes"},{"issue":"1","key":"2280_CR140","doi-asserted-by":"publisher","first-page":"15","DOI":"10.2337\/dbi18-0045","volume":"68","author":"D Daniels","year":"2018","unstructured":"Daniels D, Mietlicki-Baase EG. Glucagon-like peptide 1 in the brain: where is it coming from, where is it going? Diabetes. 2018;68(1):15\u20137. https:\/\/doi.org\/10.2337\/dbi18-0045.","journal-title":"Diabetes"},{"issue":"2","key":"2280_CR141","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3803\/EnM.2021.979","volume":"36","author":"JH Baik","year":"2021","unstructured":"Baik JH. Dopaminergic control of the feeding circuit. Endocrinol Metab. 2021;36(2):229\u201339. https:\/\/doi.org\/10.3803\/EnM.2021.979.","journal-title":"Endocrinol Metab"},{"issue":"13","key":"2280_CR142","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2411069122","volume":"122","author":"W Ariyani","year":"2025","unstructured":"Ariyani W, Yoshikawa C, Tsuneoka H, Amano I, Imayoshi I, Ichinose H, et al. Dopaminergic neurons in the paraventricular hypothalamus extend the food consumption phase. Proc Natl Acad Sci U S A. 2025;122(13):e2411069122. https:\/\/doi.org\/10.1073\/pnas.2411069122.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"2280_CR143","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/j.beem.2014.03.003","volume":"28","author":"A Joly-Amado","year":"2014","unstructured":"Joly-Amado A, Cansell C, Denis RGP, Delbes A-S, Castel J, Martinez S, et al. The hypothalamic arcuate nucleus and the control of peripheral substrates. Best Pract Res Clin Endocrinol Metab. 2014;28(5):725\u201337. https:\/\/doi.org\/10.1016\/j.beem.2014.03.003.","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"6","key":"2280_CR144","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1016\/j.cmet.2014.10.004","volume":"20","author":"BL Panaro","year":"2014","unstructured":"Panaro BL, Tough IR, Engelstoft MS, Matthews RT, Digby GJ, M\u00f8ller CL, et al. The melanocortin-4 receptor is expressed in enteroendocrine L cells and regulates the release of peptide YY and glucagon-like peptide 1 in vivo. Cell Metab. 2014;20(6):1018\u201329. https:\/\/doi.org\/10.1016\/j.cmet.2014.10.004.","journal-title":"Cell Metab"},{"key":"2280_CR145","doi-asserted-by":"publisher","DOI":"10.1016\/j.peptides.2023.171138","volume":"173","author":"R Spezani","year":"2024","unstructured":"Spezani R, Marinho TS, Reis TS, Aguila MB, Mandarim-de-Lacerda CA. Cotadutide (GLP-1\/Glucagon dual receptor agonist) modulates hypothalamic orexigenic and anorexigenic neuropeptides in obese mice. Peptides. 2024;173:171138. https:\/\/doi.org\/10.1016\/j.peptides.2023.171138.","journal-title":"Peptides"},{"issue":"1","key":"2280_CR146","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/oby.2008.461","volume":"17","author":"FL Greenway","year":"2009","unstructured":"Greenway FL, Whitehouse MJ, Guttadauria M, Anderson JW, Atkinson RL, Fujioka K, et al. Rational design of a combination medication for the treatment of obesity. Obesity. 2009;17(1):30\u20139. https:\/\/doi.org\/10.1038\/oby.2008.461.","journal-title":"Obesity"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-025-02280-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-025-02280-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-025-02280-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T05:00:52Z","timestamp":1774069252000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-025-02280-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,12]]},"references-count":146,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["2280"],"URL":"https:\/\/doi.org\/10.1007\/s40265-025-02280-z","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,12]]},"assertion":[{"value":"30 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"C.L.R. is principal investigator at Seattle Children\u2019s Research Institute. He received research funding for conducting clinical trials at Seattle Children\u2019s Hospital using setmelanotide (Rhythm Pharmaceuticals). He also received compensation for consulting and advisory board participation (Rhythm Pharmaceuticals). N.J.D. is local co- investigator of the Transcend Study (Rhythm Pharmaceuticals) and received an unrestricted grant and reimbursement of travel expenses for a scientific meeting from Rhythm Pharmaceuticals. H.M.v.S is local primary investigator of the Transcend Study (Rhythm Pharmaceuticals), and has received funding from Pfizer, Novo Nordisk and Rhythm Pharmaceuticals for the organization of the ESPE Science Symposium as well as the 6th Craniopharyngioma Post-graduate Course. In addition, she has received reimbursement of travel expenses for a scientific meeting by Rhythm Pharmaceuticals and received funding for research projects from both Rhythm Pharmaceuticals and Pfizer.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"The first outline of the paper was drafted by CLR. NDO created Fig.\n                      \n                      . All authors contributed equally to writing the different sections and have read and approved the final version of the manuscript.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}